border=0
border=0
Enter any ticker symbol here to see the live quote & chart tools in action
Ticker:   
border=0 border=0 Benefits: /
  • Your filings are automatically published to your site as they are filed.
  • Investors don't have to leave your site to see filings.


    • Product Description
  • Once a report has been filed with the SEC it will be available on the website.


    • SEC Filings Section 16 Filings Only
     
    NOVADEL PHARMA INC filed this 10-Q on 11/01/2011.
    Click on link to view section or document
    1. Entire Document including Exhibit(s)
    2. 10-Q - FORM 10-Q
    PAGE: 1 - UNITED STATES
    PAGE: 2 - NovaDel Pharma Inc.
    PAGE: 3 - PART I. FINANCIAL INFORMATION
    PAGE: 4 - NovaDel Pharma Inc.
    PAGE: 5 - NovaDel Pharma Inc.
    PAGE: 6 - NovaDel Pharma Inc.
    PAGE: 7 - NovaDel Pharma Inc.
    PAGE: 8 - Note 4 Earnings or Loss Per Share
    PAGE: 9 - Derivatives and Hedging.
    PAGE: 10 - Derivatives and Hedges
    PAGE: 11 - Note 7 Revenue from Licensing Agreements
    PAGE: 12 - Note 8 Share-Based Compensation
    PAGE: 13 - Note 10 Recent Accounting Pronouncements
    PAGE: 14 - Item 2. Management s Discussion and Analysis of Financial Condition and Results of Operations
    PAGE: 15 - Duromist
    PAGE: 16 - NVD-201
    PAGE: 17 - Comparison of the Nine Months ended September 30, 2011 and 2010
    PAGE: 18 - Liquidity and Capital Resources
    PAGE: 19 - Critical Accounting Policies and Estimates
    PAGE: 20 - Recent Accounting Pronouncements
    PAGE: 21 - PART II. OTHER INFORMATION
    PAGE: 22 - We will require significant capital for product development and commercialization in the near term.
    PAGE: 23 - Our technology platform is based solely on our proprietary drug delivery technology. Our ongoing cli
    PAGE: 24 - We do not have direct consumer marketing experience.
    PAGE: 25 - We face intense competition.
    PAGE: 26 - The clinical trial and regulatory approval process for our products is expensive and time consuming,
    PAGE: 27 - Our strategy includes entering into collaboration agreements with third parties for certain of our p
    PAGE: 28 - If we cannot protect our intellectual property, other companies could use our technology in competit
    PAGE: 29 - Even if we obtain patents to protect our products, those patents may not be sufficiently broad and o
    PAGE: 30 - Our inability to manage the future growth that we are attempting to achieve could severely harm our
    PAGE: 31 - Compliance with changing regulation of corporate governance and public disclosure may result in addi
    PAGE: 32 - Provisions of our certificate of incorporation and Delaware law could deter a change of our manageme
    PAGE: 33 - The market price of our stock and our earnings may be adversely affected by market volatility.
    PAGE: 34 - Penny stock regulations may impose certain restrictions on marketability of our securities.
    PAGE: 35 - Shares eligible for future sale may adversely affect the market.
    PAGE: 36 - We may incur significant costs from class action litigation due to our expected stock volatility.
    PAGE: 37 - Item 6. Exhibits
    PAGE: 38 - SIGNATURES
    3. EX-10.2 - LICENSE AND DISTRIBUTION AGREEMENT
    PAGE: 1 - Exhibit 10.2
    PAGE: 2 - 1.3 Calendar Quarter
    PAGE: 3 - 1.15 Executives
    PAGE: 4 - 1.25 MAA
    PAGE: 5 - 1.37 Regulatory Authority
    PAGE: 6 - (b)
    PAGE: 7 - 2.5 Exclusivity.
    PAGE: 8 - (b) Correspondence with Regulatory Authorities.
    PAGE: 9 - (iii)
    PAGE: 10 - 4.1 Payments.
    PAGE: 11 - 5.1 Ownership of Intellectual Property.
    PAGE: 12 - 5.4 Infringement of Third Party Rights.
    PAGE: 13 - 6.1 Mutual Representations and Warranties.
    PAGE: 14 - (g)
    PAGE: 15 - 7.1 Confidential Information.
    PAGE: 16 - 7.4 Publications.
    PAGE: 17 - 8.1 Term.
    PAGE: 18 - (e)
    PAGE: 19 - (v) Disposition of Inventory.
    PAGE: 20 - 9.1 Indemnification by NovaDel.
    PAGE: 21 - 9.3 Indemnification Procedure.
    PAGE: 22 - (iii) Settlement.
    PAGE: 23 - 10.1 Disputes.
    PAGE: 24 - 11.3 Relationship Between the Parties.
    PAGE: 25 - 11.6 No Third Party Beneficiaries.
    PAGE: 26 - 11.9 Force Majeure.
    PAGE: 27 - 11.11 Counterparts.
    PAGE: 28 - Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith omit
    PAGE: 29 - SCHEDULE 1.29
    PAGE: 30 - SCHEDULE 1.41
    PAGE: 31 - SCHEDULE 4.3
    PAGE: 32 - SCHEDULE 6.2
    4. EX-31.1 - SECTION 302 CERTIFICATION PRINCIPAL EXECUTIVE, FINANCIAL AND ACCOUNTING OFFICER
    PAGE: 1 - EXHIBIT 31.1
    5. EX-32.1 - SECTION 906 CERTIFICATION PRINCIPAL EXECUTIVE, FINANCIAL AND ACCOUNTING OFFICER
    PAGE: 1 - EXHIBIT 32.1
    6. EX-101.INS - XBRL INSTANCE DOCUMENT
    7. EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
    8. EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
    9. EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
    10. EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE
    11. EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE




    border=0
    Quote & Chart Package
    Basic Stock Chart
    Basic Stock Quote
    Embedded Quote / Chart
    Embedded Full Quote / Chart
    Interactive Chart
    Intraday Chart
    Pop Up Quote
    Scrolling Ticker

    You are viewing our Quote and Chart Demo using ticker symbol NVDL
    border=0

    T 800.650.1211     F 888.329.6696     E info@stockgroup.com   © 2004 Stockgroup Media Inc.    Disclaimer